A Comprehensive Toxicity and Efficacy Analysis of Different Bridging Therapies Prior to Anti CD19-CAR-T Cell Therapy in Patients with DLBCL- a National Multi-Center Cohort Study

Ron Ram,Sigal Grisariu,Liat Shargian-Alon,Dana Yehudai-Ofir,Irit Avivi,Orit Gutfeld,Polina Stepensky,Tsila Zuckerman,Moshe Yeshurun,Odelia Amit,Batia Avni,Ronit Gurion,Yael Bar-On,Ofrat Beyar-Katz,Ronit Gold,Shimrit Ringelstein,Itai Levi,Tzvi Porges,Chava Perry

Blood（2021）

引用 0|浏览9

暂无评分

摘要

Introduction - Data regarding efficacy and toxicity of different bridging strategies prior to CAR-T therapy are scanty. Tisagenlecleucel (Kymriah TM, Novartis) and axictagene ciloleucel (Yescarta TM, Kite/Gilead) were commercially approved for relapsed/refractory (R/R) DLBCL since 2019. We analyzed real-life data of CAR-T therapy among all consecutive patients who were treated in 4 different CAR-T centers in Israel.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要